https://www.selleckchem.com/pr....oducts/pyrvinium.htm
adjuvant chemotherapy, should be considered for patients with advanced GBCs. Recurrent hepatitis C virus (HCV) infection of transplanted liver allografts is universal in patients with detectable HCV viremia at the time of transplantation. Direct-acting antiviral (DAA) therapy has been adopted as the standard of care for recurrent HCV infection in the post-transplant setting. However, there are insufficient data regarding its efficacy in liver transplant (LT) recipients with a history of hepatocellular carcinoma (HCC), and the risk of
Like
Comment
Share
